Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab induced decreases of PLA2Rab in MN: a pilot study
2025-521139-35-01Phase 2Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG), sponsored by Radboud University Medical Center. Primary endpoint: Disappearance rate (half-life) of anti-PLA2R antibodies. Planned start Jul 2025; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2025-521139-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521139-35-01.